A&M STABTEST
One-Stop Shop for Specialized Bioanalytical Services

Lead times must be carefully managed in nonclinical and clinical product development due to the enormous volume of work involved. Given today’s time constraints and the high cost of discovery and development in pharmaceutical research, supporting bioanalysis services a more vital than ever to ensure the speed and success of projects.

It is well-acknowledged and globally accepted that the emergence of bioanalysis has become a critical tool in developing new drugs. Outsourcing bioanalysis enables companies to handle more complex or repetitive tasks and allows them to focus on their core competencies. Today, many pharmaceutical and biotechnology companies outsource their bioanalytical needs. As the demand for outsourcing grows at every stage of biopharmaceutical development, A&M STABTEST offers bioanalytical services exclusively to the pharmaceutical industry.

Since its inception in 1995 as a company that provided services for pharmaceutical stability testing, the privately-owned firm has established itself as a specialist in the pharmaceutical analysis of small molecules and biomolecules. Building on its 27 years of experience in the pharmaceutical environment, the company ensures its services are always compliant with the latest national and international regulatory requirements. A&M STABTEST has two lab testing facilities, in Mainz, Germany, which deals with small molecule drugs and another in Bergheim, which specializes in biopharmaceuticals and Advanced. Therapy Medicinal Products (ATMP). Combined, they offer all the required bioanalytical services.

“As privately owned organization the owners ensure that the revenue generated is continually invested in modern analytical equipment and technologies to ensure the company remains central Europe’s largest provider of pharmaceutical analysis,” says Dr Steven A. Watt, Head of Business Development. Since projects are organized in teams at each site, our employees are quick to distinguish between lab faults and product failures. It facilitates efficient and knowledgeable communication between clients and the relevant project team.

In these demanding times A&M STABTEST has implemented a taskforce to proactively anticipate any disruption in the supply chain, and identify alternative sources to avoid shortages. Since the ongoing COVID pandemic and the conflict in Ukraine have contributed to the disruption of supply chains, the company has invested substantially in the storage and stocking of in-demand supplies.

A&M STABTEST creates a transparent working environment by providing high quality analytics, from a single laboratory site that allows clients an overview of their products, even in the early stages of testing. More than 250 dedicated specialists work on small molecules and biopharmaceuticals, performing routine analytical services as well as specialized analysis such as, mass spectrometry cell based bioassays, testing of inhalable products and analytical development.

A&M STABTEST develops and expands its services to remain a competent partner in the market by maintaining a constant dialogue with customers regarding future innovations in pharmaceutical research and development. The company also continuously invests in modern analytical equipment and technologies and educates its employees on utilizing this tech to its full potential. Looking ahead, the company is also developing analytical solutions for the next generation of cell and gene therapies.